In a report issued on August 8, Keay Nakae from Chardan Capital reiterated a Hold rating on Dicerna Pharma (NASDAQ: DRNA), with a price target of $14.50. The company’s shares closed on Friday at $14.60, close to its 52-week high of $15.80.
According to TipRanks.com, Nakae has 0 stars on 0-5 star ranking scale with an average return of -19.3% and a 28.8% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma Corporation, Arcturus Therapeutics Ltd, and Arrowhead Research.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Dicerna Pharma with a $16.17 average price target.
See today’s analyst top recommended stocks >>
Based on Dicerna Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $35.64 million. In comparison, last year the company had a GAAP net loss of $15.23 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases using its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas.
